Hikma Pharmaceuticals

OverviewSuggest Edit

Hikma is a multinational pharmaceutical group dedicated to improving the health and wellbeing of people in the markets it serves through the development, manufacturing and marketing of a broad range of solid, liquid and injectable generic and in-licensed pharmaceutical products.
Hikma is a leading generic pharmaceutical company with a significant presence in the Middle East and North Africa (MENA) region, the United States and Europe. It was first listed on the London Stock Exchange in 2005 is now a constituent of the FTSE 100 Index.

TypePublic
Founded1978
HQLondon, GB
Websitehikma.com
Employee Ratings3.7
Overall CultureF

Latest Updates

Employees (est.) (Jun 2022)8,700(+2%)
Job Openings138
Revenue (FY, 2021)$2.6 B(+10%)
Share Price (Jun 2022)£16.5(-1%)
Cybersecurity ratingCMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Hikma Pharmaceuticals

John Castellani

John Castellani

CREC Chair, Independent Non-Executive Director
Said Darwazah

Said Darwazah

Executive Chairman
Robert Pickering

Robert Pickering

Nomination and Governance Committee Chair, Senior Independent Director
Pat Butler

Pat Butler

Chair of Audit Committee
Siggi Olafsson

Siggi Olafsson

Chief Executive Officer
Nina Henderson

Nina Henderson

Independent Non-Executive Director
Show more

Hikma Pharmaceuticals Office Locations

Hikma Pharmaceuticals has offices in London, Berkeley Heights, Bouira, Rahmania and in 14 other locations
London, GB (HQ)
1 New Burlington Pl, Mayfair
Bouira, DZ
Zone D'Activite
Planegg, DE
Lochhamer Str. 13
Pavia, IT
Viale Certosa di Pavia, 10
Amman, JO
King Abdallah Ben Al Hussein Ath Thani
Al Kuwayt, KW
Ahmad Al Jaber St
Show all (22)

Hikma Pharmaceuticals Financials and Metrics

Hikma Pharmaceuticals Revenue

Hikma Pharmaceuticals's revenue was reported to be $2.55 b in FY, 2021
USD

Revenue (FY, 2021)

2.6b

Gross profit (FY, 2021)

1.5b

Net income (FY, 2021)

420.0m

EBITDA (FY, 2021)

765.0m

EBIT (FY, 2021)

619.0m

Market capitalization (29-Jun-2022)

3.8b

Closing stock price (29-Jun-2022)

16.5

Cash (31-Dec-2021)

426.0m

EV

4.2b
Hikma Pharmaceuticals's current market capitalization is £3.8 b.
Annual
USDFY, 2018FY, 2019FY, 2020FY, 2021

Revenue

2.1b2.2b2.3b2.6b

Cost of goods sold

(959.0m)(960.0m)(1.0b)(1.1b)

Gross profit

1.1b1.3b1.4b1.5b

R&D expense

(142.0m)(150.0m)(137.0m)(143.0m)
Half Year
USDH1, 2019H1, 2020H1, 2021

Revenue

1.0b1.1b1.2b

Cost of goods sold

(440.0m)(499.0m)(568.0m)

Gross profit

607.0m639.0m678.0m

R&D expense

(72.0m)(62.0m)(59.0m)
Annual
USDFY, 2018FY, 2019FY, 2020FY, 2021

Cash

276.0m442.0m323.0m426.0m

Accounts Receivable

654.0m637.0m662.0m781.0m

Prepaid Expenses

151.0m161.0m127.0m157.0m

Inventories

528.0m568.0m757.0m695.0m
Half Year
USDH1, 2019H1, 2020H1, 2021

Cash

322.0m413.0m322.0m

Accounts Receivable

610.0m560.0m693.0m

Prepaid Expenses

129.0m175.0m163.0m

Inventories

579.0m684.0m736.0m
Annual
USDFY, 2018FY, 2019FY, 2020FY, 2021

Net Income

293.0m491.0m558.0m544.0m

Depreciation and Amortization

121.0m90.0m79.0m133.0m

Inventories

(51.0m)(25.0m)(180.0m)38.0m

Accounts Payable

88.0m(6.0m)6.0m14.0m
Half Year
USDH1, 2019H1, 2020H1, 2021

Net Income

226.0m274.0m319.0m

Depreciation and Amortization

59.0m27.0m27.0m

Inventories

(48.0m)(111.0m)11.0m
USDFY, 2018

Revenue/Employee

244.8k
Show all financial metrics

Hikma Pharmaceuticals Revenue Breakdown

Embed Graph

Hikma Pharmaceuticals revenue breakdown by business segment: 32.1% from PHARMACEUTICAL GENERIC, 26.2% from BRANDED PHARMACEUTICAL, 41.2% from INJECTABLE PHARMACEUTICAL and 0.4% from Other

Hikma Pharmaceuticals revenue breakdown by geographic segment: 59.2% from UNITED STATES, 33.2% from MIDDLE EAST AND NORTH AFRICA, 7.4% from EUROPE AND REST OF THE WORLD and 0.2% from Other

Hikma Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

C

72/100

SecurityScorecard logo

Hikma Pharmaceuticals Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

50-59

out of 100

CSRHub logo

Hikma Pharmaceuticals Online and Social Media Presence

Embed Graph

Hikma Pharmaceuticals Company Culture

  • Overall Culture

    F

    46/100

  • CEO Rating

    F

    50/100

  • Compensation

    C-

    62/100

Learn more on Comparably

Hikma Pharmaceuticals News and Updates

Hikma Pharmaceuticals sees revenue soar on strong demand for Covid treatment drugs

London-based Hikma Pharmaceuticals has said it expects a huge rise in annual core operating profit for the year, after being The post Hikma Pharmaceuticals sees revenue soar on strong demand for Covid treatment drugs appeared first on CityAM.

London Markets: Hikma Pharmaceuticals soars on dividend hike but U.K. stocks falter

Hikma Pharmaceuticals led the way for the U.K.'s FTSE 100 index as the stock surged 11.3%.

Generic Oncology Drugs Market Detailed In New Research Report By Top Most Key Mylan, Aurobindo Pharma, Hikma Pharmaceuticals, Natco Pharma

The global Oncology Drugs market also give a gist on the upcoming players in the market who are ready to compete with the existing ones. This section climaxes the major statistics about the key players who are engaged in development, manufacturing, distribution, and sales, which is also included in …

Inhalation Anesthesia Market Present Scenario and the Growth Prospects 2018 – 2026 Analysis By Global Players Baxter International, Inc., Mylan NV, AbbVie, Inc., Hikma Pharmaceuticals, Piramal Healthcare etc.

Inhalation Anesthesia Market study provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players. It profiles leading players in the Global Inhalation Anesthesia Market based on the…

Hikma Pharmaceuticals Blogs

#OwnYourCareer | Lisa Poulos, Project Manager IT PMO - Berkeley Heights, New Jersey, US

Meet Lisa Poulos, Project Manager IT PMO at our Berkeley Heights, New Jersey, US site and discover why she loves working at Hikma!

Hikma enters the French generic injectables market, expanding European presence

London, 13 June 2022 – Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical group, is pleased to announce the establishment of Hikma France S.A.S. (Hikma France). This marks Hikma’s official entry into France, which has the second largest pharmaceutical market in Europe and a generic …

#OwnYourCareer | Rachel Elliott, Sr. Project Manager IT. Columbus, Ohio

Meet Rachel Elliott, Sr. Project Manager IT at our Columbus, Ohio, US site and discover why she loves working at Hikma!

Siggi Olafsson to step down as Chief Executive

London, 24 May 2022 – Hikma Pharmaceuticals PLC (Hikma) today announces that Siggi Olafsson has resigned as Chief Executive Officer (CEO), and from Hikma’s Board of Directors, to pursue other opportunities.

Section 430(2B) Companies Act 2006 Statement

Hikma Pharmaceuticals PLC (“Hikma”) announced earlier today that Siggi Olafsson has resigned as Chief Executive Officer and from Hikma’s Board of Directors. As required by section 430(2B) of the Companies Act 2006, details of the remuneration payments made to or to be made to Siggi Olafsson are set …

#OwnYour Career | Kristina Stumpf, Key Account Manager. Germany

Meet Kristina Stumpf, Key Account Manager at our Germany site and discover why she loves working at Hikma!
Show more

Hikma Pharmaceuticals Frequently Asked Questions

  • When was Hikma Pharmaceuticals founded?

    Hikma Pharmaceuticals was founded in 1978.

  • Who are Hikma Pharmaceuticals key executives?

    Hikma Pharmaceuticals's key executives are John Castellani, Said Darwazah and Robert Pickering.

  • How many employees does Hikma Pharmaceuticals have?

    Hikma Pharmaceuticals has 8,700 employees.

  • What is Hikma Pharmaceuticals revenue?

    Latest Hikma Pharmaceuticals annual revenue is $2.6 b.

  • What is Hikma Pharmaceuticals revenue per employee?

    Latest Hikma Pharmaceuticals revenue per employee is $293.4 k.

  • Who are Hikma Pharmaceuticals competitors?

    Competitors of Hikma Pharmaceuticals include Pierre Fabre, Zuellig Pharma and Teva.

  • Where is Hikma Pharmaceuticals headquarters?

    Hikma Pharmaceuticals headquarters is located at 1 New Burlington Pl, Mayfair, London.

  • Where are Hikma Pharmaceuticals offices?

    Hikma Pharmaceuticals has offices in London, Berkeley Heights, Bouira, Rahmania and in 14 other locations.

  • How many offices does Hikma Pharmaceuticals have?

    Hikma Pharmaceuticals has 22 offices.